SCHEMBL30776299

SCHEMBL30776299

Cc1nc(N2C[C@H]3C[C@@H]2CN3C(=O)OC(C)(C)C)c2c3c(c(-c4ccc(F)c5sc(NC(=O)OC(C)(C)C)c(C#N)c45)c(F)c2n1)COC3

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
RET P07949 2/20 0.33
HDAC1 Q13547 1/20 0.32
PARP1 P09874 1/20 0.31
GPR119 Q8TDV5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26532506 1.00 RET (0.33) RETHDAC1PARP1GPR119
SCHEMBL27084375 0.95
SCHEMBL26533798 0.88 GPR119 (0.35) RETHDAC1PARP1GPR119
SCHEMBL26533794 0.88 GPR119 (0.35) RETHDAC1PARP1GPR119
SCHEMBL30587246 0.88 GPR119 (0.35) RETHDAC1PARP1GPR119
SCHEMBL30587289 0.86 GPR119 (0.34) RETHDAC1GPR119
SCHEMBL26532739 0.86 GPR119 (0.34) RETHDAC1GPR119
SCHEMBL30776423 0.84 EIF4EBP1 (0.31)
SCHEMBL30776384 0.84 KRAS (0.35) GPR119
SCHEMBL26533910 0.84 KRAS (0.35) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289830-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2025-09-18 US disclosed
US-12351591-B2 KRas inhibitors ELI LILLY AND COMPANY (US) 2025-07-08 US disclosed
US-20240043451-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043451-A1 KRAS INHIBITORS KRAS, NRAS, HRAS RET 42/4885HDAC1 1452/4885PARP1 483/4885
US-12351591-B2 KRas inhibitors KRAS, NRAS, HRAS RET 42/4885HDAC1 1452/4885PARP1 483/4885
US-20250289830-A1 KRAS INHIBITORS KRAS, NRAS, HRAS RET 42/4885HDAC1 1452/4885PARP1 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.